CSL Limited
CSL
Ранг среди акций
#363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Цена акции
$138.58
Рыночная капитализация
$66.50B
Изменение (1 день)
0.72%
Изменение (1 год)
-2.29%
Страна
AU
Торговля CSL Limited (CSL)
Категория
Healthcare
Коэффициент P/B для CSL Limited (CSL)
Коэффициент P/B на October 2026 TTM: 4.21
Согласно последним финансовым отчетам и цене акций CSL Limited, текущий коэффициент P/B (TTM) составляет 4.21. В конце 2024 он составлял 5.43.
История P/B для CSL Limited с 2000 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 4.21 | 6.80% |
| 2025 | 3.94 | -27.38% |
| 2024 | 5.43 | 44.67% |
| 2023 | 3.75 | -8.59% |
| 2022 | 4.11 | -64.62% |
| 2021 | 11.60 | -41.84% |
| 2020 | 19.95 | 52.81% |
| 2019 | 13.06 | -17.71% |
| 2018 | 15.87 | -20.12% |
| 2017 | 19.87 | 32.34% |
| 2016 | 15.01 | -0.22% |
| 2015 | 15.04 | 47.75% |
| 2014 | 10.18 | 1.25% |
| 2013 | 10.06 | 70.32% |
| 2012 | 5.91 | 28.39% |
| 2011 | 4.60 | -10.55% |
| 2010 | 5.14 | 17.45% |
| 2009 | 4.38 | -40.16% |
| 2008 | 7.31 | -12.44% |
| 2007 | 8.35 | 25.21% |
| 2006 | 6.67 | 58.64% |
| 2005 | 4.21 | 53.56% |
| 2004 | 2.74 | 23.37% |
| 2003 | 2.22 | -67.73% |
| 2002 | 6.88 | -56.70% |
| 2001 | 15.89 | 71.69% |
| 2000 | 9.25 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | 48.55% |
US
|
|
| 13.2547 | 214.99% |
US
|
|
| - | - |
CH
|
|
| 6.1824 | 46.92% |
NL
|
|
| 3.2932 | -21.74% |
BE
|
